83 related articles for article (PubMed ID: 22468892)
21. Novel, negatively charged, human serum albumins display potent and selective in vitro anti-human immunodeficiency virus type 1 activity.
Jansen RW; Schols D; Pauwels R; De Clercq E; Meijer DK
Mol Pharmacol; 1993 Nov; 44(5):1003-7. PubMed ID: 7902528
[TBL] [Abstract][Full Text] [Related]
22. Recent progress in the development of coumarin derivatives as potent anti-HIV agents.
Yu D; Suzuki M; Xie L; Morris-Natschke SL; Lee KH
Med Res Rev; 2003 May; 23(3):322-45. PubMed ID: 12647313
[TBL] [Abstract][Full Text] [Related]
23. Rational conversion of noncontinuous active region in proteins into a small orally bioavailable macrocyclic drug-like molecule: the HIV-1 CD4:gp120 paradigm.
Hurevich M; Swed A; Joubran S; Cohen S; Freeman NS; Britan-Rosich E; Briant-Longuet L; Bardy M; Devaux C; Kotler M; Hoffman A; Gilon C
Bioorg Med Chem; 2010 Aug; 18(15):5754-61. PubMed ID: 20619663
[TBL] [Abstract][Full Text] [Related]
24. A peptidomimetic HIV-entry inhibitor directed against the CD4 binding site of the viral glycoprotein gp120.
Neffe AT; Meyer B
Angew Chem Int Ed Engl; 2004 May; 43(22):2937-40. PubMed ID: 15170309
[No Abstract] [Full Text] [Related]
25. The role of receptors in the HIV-1 entry process.
Jones R; Nelson M
Eur J Med Res; 2007 Oct; 12(9):391-6. PubMed ID: 17933719
[TBL] [Abstract][Full Text] [Related]
26. Enabled clinical use of an HIV-1 attachment inhibitor through drug delivery.
Timmins P; Brown J; Meanwell NA; Hanna GJ; Zhu L; Kadow JF
Drug Discov Today; 2014 Sep; 19(9):1288-93. PubMed ID: 24727410
[TBL] [Abstract][Full Text] [Related]
27. Synthetic CD4 exocyclics inhibit binding of human immunodeficiency virus type 1 envelope to CD4 and virus replication in T lymphocytes.
Zhang X; Gaubin M; Briant L; Srikantan V; Murali R; Saragovi U; Weiner D; Devaux C; Autiero M; Piatier-Tonneau D; Greene MI
Nat Biotechnol; 1997 Feb; 15(2):150-4. PubMed ID: 9035140
[TBL] [Abstract][Full Text] [Related]
28. Design, synthesis, and biological evaluation of chicoric acid analogs as inhibitors of HIV-1 integrase.
Charvat TT; Lee DJ; Robinson WE; Chamberlin AR
Bioorg Med Chem; 2006 Jul; 14(13):4552-67. PubMed ID: 16524737
[TBL] [Abstract][Full Text] [Related]
29. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
30. New bis(thiosemicarbazonate) gold(III) complexes inhibit HIV replication at cytostatic concentrations: potential for incorporation into virostatic cocktails.
Fonteh PN; Keter FK; Meyer D
J Inorg Biochem; 2011 Sep; 105(9):1173-80. PubMed ID: 21708102
[TBL] [Abstract][Full Text] [Related]
31. Studies of anti-HIV transcription inhibitor quinolones: identification of potent N1-vinyl derivatives.
Tabarrini O; Massari S; Daelemans D; Meschini F; Manfroni G; Bottega L; Gatto B; Palumbo M; Pannecouque C; Cecchetti V
ChemMedChem; 2010 Nov; 5(11):1880-92. PubMed ID: 20928882
[TBL] [Abstract][Full Text] [Related]
32. Combination therapy in the management of HIV infection.
Vella S; Franca Pirillo M
Methods Find Exp Clin Pharmacol; 1996; 18 Suppl C():23-6. PubMed ID: 9003571
[No Abstract] [Full Text] [Related]
33. Immunomodulatory effects of antiretroviral chemotherapy.
Schooley RT
J Biol Regul Homeost Agents; 1995; 9(3):110-3. PubMed ID: 8782019
[TBL] [Abstract][Full Text] [Related]
34. Contribution of Vpu, Env, and Nef to CD4 down-modulation and resistance of human immunodeficiency virus type 1-infected T cells to superinfection.
Wildum S; Schindler M; Münch J; Kirchhoff F
J Virol; 2006 Aug; 80(16):8047-59. PubMed ID: 16873261
[TBL] [Abstract][Full Text] [Related]
35. Effect of 1,25-dihydroxyvitamin D3 and its analogs on human immunodeficiency virus infection in monocytes/macrophages.
Kizaki M; Ikeda Y; Simon KJ; Nanjo M; Koeffler HP
Leukemia; 1993 Oct; 7(10):1525-30. PubMed ID: 7692190
[TBL] [Abstract][Full Text] [Related]
36. Discovery of N-benzyl-N'-(4-pipyridinyl)urea CCR5 antagonists as anti-HIV-1 agents (I): optimization of the amine portion.
Duan M; Peckham J; Edelstein M; Ferris R; Kazmierski WM; Spaltenstein A; Wheelan P; Xiong Z
Bioorg Med Chem Lett; 2010 Dec; 20(24):7397-400. PubMed ID: 21035337
[TBL] [Abstract][Full Text] [Related]
37. Feglymycin, a unique natural bacterial antibiotic peptide, inhibits HIV entry by targeting the viral envelope protein gp120.
Férir G; Hänchen A; François KO; Hoorelbeke B; Huskens D; Dettner F; Süssmuth RD; Schols D
Virology; 2012 Nov; 433(2):308-19. PubMed ID: 22959895
[TBL] [Abstract][Full Text] [Related]
38. Carbonic anhydrase inhibitors. Synthesis of water-soluble, topically effective, intraocular pressure-lowering aromatic/heterocyclic sulfonamides containing cationic or anionic moieties: is the tail more important than the ring?
Scozzafava A; Menabuoni L; Mincione F; Briganti F; Mincione G; Supuran CT
J Med Chem; 1999 Jul; 42(14):2641-50. PubMed ID: 10411484
[TBL] [Abstract][Full Text] [Related]
39. New in silico and conventional in vitro approaches to advance HIV drug discovery and design.
Maga G; Veljkovic N; Crespan E; Spadari S; Prljic J; Perovic V; Glisic S; Veljkovic V
Expert Opin Drug Discov; 2013 Jan; 8(1):83-92. PubMed ID: 23167743
[TBL] [Abstract][Full Text] [Related]
40. Highly potent inhibition of human immunodeficiency virus type 1 replication by TAK-220, an orally bioavailable small-molecule CCR5 antagonist.
Takashima K; Miyake H; Kanzaki N; Tagawa Y; Wang X; Sugihara Y; Iizawa Y; Baba M
Antimicrob Agents Chemother; 2005 Aug; 49(8):3474-82. PubMed ID: 16048963
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
